L-threonine methyl ester hydrochloride | 39994-75-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苏氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-threonine methyl ester hydrochloride
• 英文别名: (L)-Threonine methyl ester hydrochloride；(2S)-3-hydroxy-1-methoxy-1-oxobutan-2-aminium chloride；Thr-OMe hydrochloride；DL-Threonine methyl ester hydrochloride；L-threonine methyl ester, hydrochloride；l-Threonine methyl ester chlorhydrate；methyl (2S)-2-amino-3-hydroxybutanoate;hydrochloride
• CAS: 39994-75-7；60538-15-0；60538-18-3；62076-66-8；76419-75-5；79617-27-9；108724-12-5
• 化学式: C₅H₁₁NO₃*ClH
• 分子量: 169.608
• InChiKey: OZSJLLVVZFTDEY-LXNQBTANSA-N

物化性质

• 熔点：
  64 °C
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
• 稳定性/保质期：
  常规情况下不会分解，也没有危险的反应。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.71
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  72.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25,S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29225000
• 危险品运输编号：
  OTH
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封、阴凉、干燥处保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Allo-Thr-OMe HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Allo-Thr-OMe HCl
CAS number: 79617-27-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11NO3.ClH
Molecular weight: 169.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

在1000 mL三口圆底烧瓶中，依次加入45 g L-苏氨酸（0.38 mol）和400 mL无水甲醇。将混合物置于冰盐浴冷却下，缓慢通入干燥的氯化氢气体（自制：采用浓硫酸、浓盐酸、氯化钠制备，并经浓硫酸干燥）。约4小时后固体完全消失。随后加热至回流反应3小时，再次冷却并继续通入干燥氯化氢气体直至饱和（通过称重确认质量不变），室温下再进行约3天的反应。TLC显示反应完全后，减压蒸除溶剂，得到L-苏氨酸甲酯盐酸盐68.5 g。

反应信息

• 作为反应物：
  描述：

  4-氯苯磺酰氯 、 L-threonine methyl ester hydrochloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以98%的产率得到methyl (2S)-2-[(4-chlorophenyl)sulfonylamino]-3-hydroxy-butanoate
  参考文献：
  名称：

  [EN] NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS
  [FR] NOUVEAUX ANTAGONISTES DES RÉCEPTEURS TRPA1 DE TYPE SULFONAMIDE

  摘要：

  本发明公开了式(I)化合物。式(I)化合物是TRPA1拮抗剂，可作为药物组合物的活性成分，用于治疗疼痛和其他通过抑制TRPA1受体而缓解的病症。

  公开号：

  WO2014135617A1
• 作为产物：
  描述：

  L-threonine 生成 L-threonine methyl ester hydrochloride
  参考文献：
  名称：

  .beta.-thiopropionyl-aminoacid derivatives and their use as

  摘要：

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。

  公开号：

  US06048852A1

文献信息

• LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF
  申请人：YEDA RESEARCH AND DEVELOPMENT CO. LTD.

  公开号：US20160002269A1

  公开（公告）日：2016-01-07

  The present invention is directed to multinuclear lanthanides chiral clusters, based on phenyl-oxazoline-amide (POxA) ligands, and to methods of use thereof. The chiral clusters of this invention are highly fluorescent with high stability.

  本发明涉及基于苯基-噁唑啉酰胺（POxA）配体的多核镧系手性簇以及其使用方法。本发明的手性簇具有高荧光性能和高稳定性。
• Substituted pyrrolidin-3-yl-alkyl-piperidines
  申请人：Hoechst Marion Roussel Inc.

  公开号：US05824690A1

  公开（公告）日：1998-10-20

  The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.

  本发明涉及取代吡咯烷基哌啶基的化合物及其立体异构体和药学上可接受的盐以及其制备方法。本发明的化合物在药理活性方面具有用途，如快速激肽拮抗作用，特别是物质P和神经激肽A的拮抗作用等。具有快速激肽拮抗性质的化合物适用于与神经源性炎症和本文所述的其他疾病相关的情况。
• Singlet Oxygen Photooxidation of Peptidic Oxazoles and Thiazoles
  作者：Alessandro Manfrin、Nadine Borduas-Dedekind、Kate Lau、Kristopher McNeill

  DOI：10.1021/acs.joc.8b02684

  日期：2019.3.1

  present in the environment and in natural waters. From previous studies, they seem susceptible to oxidation by singlet oxygen (1O2); therefore, we designed and synthesized model oxazole- and thiazole-peptides and measured their 1O2 bimolecular reaction rate constants, showing slow photooxidation under environmental conditions. We reasoned their stability through the electron-withdrawing effect of the carboxamide

  恶唑和噻唑通常在非核糖体肽（NRP）和核糖体合成的翻译后修饰肽（RiPPs）中发现，它们是环境和天然水中存在的重要生物分子。从以前的研究来看，它们似乎很容易被单线态氧（1O2）氧化。因此，我们设计并合成了模型恶唑和噻唑肽，并测量了它们的1O2双分子反应速率常数，在环境条件下显示出缓慢的光氧化作用。我们通过羧酰胺取代基的吸电子作用推论了它们的稳定性。阐明了反应产物并支持了涉及环加成反应然后进行一系列重排的反应机理。RiPP的第一个1O2双分子反应速率常数，
• Compounds for inhibiting &bgr;-amyloid peptide release and/or its synthesis
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US06211235B1

  公开（公告）日：2001-04-03

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis.

  揭示了一种抑制β-淀粉样肽释放和/或其合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还揭示了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物。
• [EN] INDOLINE ANTI-CANCER AGENTS<br/>[FR] AGENTS ANTICANCÉREUX À BASE D'INDOLINE
  申请人：JOYANT PHARMACEUTICALS INC

  公开号：WO2009134938A1

  公开（公告）日：2009-11-05

  Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.

  吲哚啉化合物具有抗有丝分裂活性，可用于治疗癌症和其他增殖性疾病。